Concepedia

Publication | Closed Access

Atenolol in Migraine Prophylaxis a Double‐blind Cross‐over Multicentre Study

DOI

47

Citations

0

References

1987

Year

Valur Johannsson, Lars Nilsson, Tommy Widelius, Tommy Jäverfalk, Peter Hellman, Jan‐Åke Åkesson, Bengt Olerud, CarI‐Lennart Gustafsson, Anders Raak, Gun Sandahl,
Headache The Journal of Head and Face Pain

Abstract

SYNOPSIS The prophylactic anti‐migraine effect of atenolol was compared to placebo in a multicentre study on 63 patients with classical and/or common migraine. The study design was double‐blind cross‐over and patients were given atenolol 100 mg o.d. or matching placebo during a study treatment period of 24 weeks. The effect of atenolol was significantly better than that of placebo: integrated headache values were reduced in 70% of the patients (p = 0.004) and the proportion of days with headache was reduced in 59% of the patients (p = 0.010). Few side effects were reported with both atenolol and placebo. This study shows atenolol to be safe and effective in the prophylactic treatment of migraine.